7th Global Summit on Cancer Therapy
Title: CD49d and CD26 are independent prognostic markers for disease progression in patients with chronic lymphocytic leukemia
Biography: Lamia Ibrahim
Objective: CLL is characterized by extremely variable clinical course. Several prognostic factors can predict disease progression and therapeutic outcomes in those patients. The aim of the present study was to evaluate the use of CD49d and CD26 as independent prognostic markers in CLL patients. Methods: The present study measured surface expression of CD49d and CD26 by three-color flow cytometry in a series of 103 previously untreated CLL patients. We evaluated the prognostic role of CD49d and CD26 to predict the risk of lymphocyte doubling, disease progression and overall survival. Results: We confirmed that CD49d and CD26 were significant predictors of lymphocyte doubling (P < 0.001 for both markers) and disease progression (P < 0.001 for both markers) but insignificant for overall survival (P = 0.303 and 0.519 respectively). Furthermore, multivariate analysis between clinical parameters and flowcytometry markers revealed that CD49d and CD26 are independent prognostic markers for lymphocyte doubling (HR = 1.487 P = 007 and HR = 2.248, P =0.014 respectively) and progression to a more advanced stage (HR = 3.191, P = 0.049 and HR = 7.887, P = 0.003). Also, concordant expression of both markers was found to improve their predictive power. Discussion: Many studies reported that CD49d and CD26 combined analysis was found to improve their power to predict the risk of lymphocyte doubling and disease progression. Conclusion: CD49d and CD26 have independent prognostic value and we suggest its use as a part of routine panel for prognostic stratification of CLL at diagnosis.
Speaker PPTs Click Here